Mylan Generic Drug Pricing Securities Class Action Settlement
Mylan has agreed to settle a securities class action over alleged generic drug price-fixing. If you purchased Mylan (NASDAQ: MYL) common stock between February 16, 2016 and May 7, 2019, you may be entitled to a cash payment based on your recognized stock losses.
Do I Qualify?
You may be eligible if:
- Investors who purchased Mylan (NASDAQ: MYL) common stock between February 16, 2016 and May 7, 2019
- You provide brokerage records showing purchase and sale dates and prices
- You submit a valid claim before July 10, 2026
Brokerage records are required. You must provide records showing your purchase dates, prices, and any sales during the class period.
File your claim through the official settlement website.
File Your Claim →What Happened?
Mylan, the generic pharmaceutical giant best known for the EpiPen, was sued by investors who alleged the company participated in an industry-wide generic drug price-fixing conspiracy. The Department of Justice launched a criminal investigation into generic drug price-fixing involving dozens of drugs including digoxin, doxycycline, and other common medications. The lawsuit alleged that Mylan's executives knew about the price-fixing conduct but concealed it from investors.
When the true scope of the DOJ investigation and Mylan's potential liability was revealed, the company's stock price declined significantly. This settlement is one of several arising from the broader generic drug price-fixing scandal that has resulted in billions of dollars in fines and settlements across the pharmaceutical industry.
How Much Will I Actually Get?
Payments are calculated based on your recognized loss from Mylan stock purchases between February 16, 2016 and May 7, 2019. Brokerage records are required. Deadline is July 10, 2026 — act soon.
Last updated: June 17, 2026 | Information verified from court records and official settlement documents.